Ptc Therapeutics (PTCT) Net Income towards Common Stockholders (2012 - 2026)

Ptc Therapeutics' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 100.32% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$177.1 million, a 129.78% decrease from a year earlier, with the FY2025 full-year figure at $634.8 million, up 274.72% from the prior year.
• Net Income towards Common Stockholders improved to -$2.8 million in Q1 2026 per PTCT's latest filing, from -$125.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $866.6 million in Q1 2025 and bottomed at -$198.9 million in Q2 2023.
• The 5-year median for Net Income towards Common Stockholders is -$109.3 million (2022), against an average of -$50.6 million.
• Across the five-year window, Net Income towards Common Stockholders surged 1046.28% in 2025 and slumped 100.32% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$170.9 million in 2022, then rose by 8.83% to -$155.8 million in 2023, then soared by 57.71% to -$65.9 million in 2024, then plunged by 90.31% to -$125.4 million in 2025, then surged by 97.76% to -$2.8 million in 2026.
• Per Business Quant, the three latest PTCT Net Income towards Common Stockholders figures stand at -$2.8 million (Q1 2026), -$125.4 million (Q4 2025), and $15.9 million (Q3 2025).